Precipio, Inc.

# Precipio, Inc. (PRPO)

Based in New Haven, Connecticut, Precipio is a healthcare biotechnology company focused on cancer diagnostics and laboratory services. The company develops and provides diagnostic blood cancer testing services, including proprietary products and reagents designed to support hematologic malignancy assessment. Its product portfolio includes IV-Cell, a proprietary cell culture media that supports simultaneous culturing of four hematopoietic cell lineages, and HemeScreen, a suite of genetic diagnostic panels for blood cancer identification and characterization.

Beyond its diagnostic products, Precipio generates revenue through biomarker testing and clinical project services provided to biopharmaceutical customers. These service offerings complement its core diagnostic business by supporting drug development and clinical research activities. The company operates as a public entity listed on Nasdaq and is incorporated in Delaware.

Precipio operates with a lean organizational structure of approximately 54 full-time employees and maintains its primary operations in the United States. The company addresses the hematologic oncology diagnostics market through both direct product sales and contract research services for pharmaceutical and biotechnology partners.